TW201333034A - 新穎抗人類ｃｔｇｆ抗體 - Google Patents
新穎抗人類ｃｔｇｆ抗體 Download PDFInfo
- Publication number
- TW201333034A TW201333034A TW101148989A TW101148989A TW201333034A TW 201333034 A TW201333034 A TW 201333034A TW 101148989 A TW101148989 A TW 101148989A TW 101148989 A TW101148989 A TW 101148989A TW 201333034 A TW201333034 A TW 201333034A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- human
- variable region
- chain variable
- ctgf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201333034A true TW201333034A (zh) | 2013-08-16 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101148989A TW201333034A (zh) | 2011-12-22 | 2012-12-21 | 新穎抗人類ｃｔｇｆ抗體 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (enExample) |
| EP (1) | EP2796550B1 (enExample) |
| JP (1) | JP6040943B2 (enExample) |
| KR (1) | KR20140107507A (enExample) |
| CN (1) | CN104011206B (enExample) |
| AR (1) | AR089425A1 (enExample) |
| BR (1) | BR112014015405A2 (enExample) |
| CA (1) | CA2859627A1 (enExample) |
| EA (1) | EA029290B1 (enExample) |
| ES (1) | ES2665851T3 (enExample) |
| IN (1) | IN2014CN04615A (enExample) |
| MX (1) | MX345019B (enExample) |
| PL (1) | PL2796550T3 (enExample) |
| PT (1) | PT2796550T (enExample) |
| TW (1) | TW201333034A (enExample) |
| WO (1) | WO2013094723A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CA3142092A1 (en) * | 2019-06-04 | 2020-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-connective tissue growth factor antibody and application thereof |
| US20230416352A1 (en) * | 2020-12-03 | 2023-12-28 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| JPWO2023238845A1 (enExample) | 2022-06-07 | 2023-12-14 | ||
| AU2023373601A1 (en) | 2022-10-31 | 2025-04-03 | Astellas Pharma Inc. | Antibody-drug conjugate containing a toll-like receptor 7/8 dual agonist compound |
| WO2024188179A1 (zh) * | 2023-03-10 | 2024-09-19 | 上海济煜医药科技有限公司 | 一种靶向ctgf的抗体或其抗原结合片段及其应用 |
| WO2025047848A1 (ja) | 2023-08-30 | 2025-03-06 | アステラス製薬株式会社 | ＩｄｅＺ改変体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| DE69433422T2 (de) | 1993-03-11 | 2004-09-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Monoklonaler anti-hiv antikörper |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6562618B1 (en) | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| MXPA01005949A (es) | 1998-12-14 | 2002-09-18 | Univ Miami | Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL2796550T3 (pl) | 2018-08-31 |
| CN104011206B (zh) | 2017-03-08 |
| MX2014007681A (es) | 2014-11-25 |
| EA201491240A1 (ru) | 2014-11-28 |
| JP6040943B2 (ja) | 2016-12-07 |
| BR112014015405A2 (pt) | 2017-06-13 |
| EP2796550A4 (en) | 2015-08-19 |
| WO2013094723A1 (ja) | 2013-06-27 |
| MX345019B (es) | 2017-01-11 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| AR089425A1 (es) | 2014-08-20 |
| EA029290B1 (ru) | 2018-03-30 |
| US9587015B2 (en) | 2017-03-07 |
| EP2796550B1 (en) | 2018-02-28 |
| CN104011206A (zh) | 2014-08-27 |
| PT2796550T (pt) | 2018-04-18 |
| IN2014CN04615A (enExample) | 2015-09-18 |
| KR20140107507A (ko) | 2014-09-04 |
| ES2665851T3 (es) | 2018-04-27 |
| US20140343258A1 (en) | 2014-11-20 |
| EP2796550A1 (en) | 2014-10-29 |
| CA2859627A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526022A (ja) | 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用 | |
| US20220185875A1 (en) | Bispecific antibody specifically bound to vegf and ang2 | |
| US10703813B2 (en) | Anti IL-34 antibodies | |
| JP6040943B2 (ja) | 新規抗ヒトｃｔｇｆ抗体 | |
| US20120253017A1 (en) | Stem cell targeting | |
| KR101999867B1 (ko) | 신규 항 인간 ngf 항체 | |
| KR101589135B1 (ko) | 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도 | |
| JP2023537422A (ja) | Ｉｌ－１１の抗体及びその使用 | |
| JP2003520595A (ja) | ヒトＩＬ−１βに対する抗体 | |
| WO2007139164A1 (ja) | ヒト化抗ヒトオステオポンチン抗体 | |
| TWI843763B (zh) | 抗人類Fn14抗體 | |
| EP2821416B1 (en) | Novel anti-human il-23 receptor antibody | |
| US20110059077A1 (en) | Humanized anti-human alpha 9-integrin antibody | |
| CN106029884A (zh) | 新型抗人pai-1抗体 | |
| US12583940B2 (en) | Monoclonal antibody which targets TFPI | |
| EP4578877A1 (en) | Antibody fusion protein targeting fap and tgf-beta, and use thereof | |
| TW202325739A (zh) | 新穎Nav1.7單株抗體 | |
| CN114127110B (zh) | 抗cgrp抗体及其应用 | |
| RU2787044C2 (ru) | АНТИТЕЛО ПРОТИВ Fn14 ЧЕЛОВЕКА | |
| WO2011004847A1 (ja) | 新規ヒト化抗ヒトα９インテグリン抗体 | |
| JP2026503565A (ja) | 全身性エリテマトーデスの治療方法 | |
| WO2025256571A1 (zh) | 靶向b7h7和cd3的双特异性抗体及其应用 | |
| TW202440643A (zh) | 抗人類ｃｘ３ｃｒ１抗體 | |
| CN121005781A (zh) | 高亲和力b7h7抗体或其抗原结合片段及其用途 |